Get started
Author

Rajat Mohindra

Observed names: Mohindra, Rajat, R. Mohindra
Observed institutions: Roche (Switzerland), Queen Mary University of London, Genentech, GlaxoSmithKline (United Kingdom), Dayanand Medical College & Hospital, GlaxoSmithKline Research & Development Limited (United Kingdom)
ORCID: 0009-0000-4233-5210
Observed ORCID: 0009-0000-4233-5210
OpenAlex ID: A5014363589
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease
2017 · David A. Lipson, Helen Barnacle, et al. · American Journal of Respiratory and Critical Care Medicine · 327
PDF
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
2016 · Steven J. Pascoe, David A. Lipson, et al. · European Respiratory Journal · 88
PDF
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
2017 · Vincent Meininger, Angela Genge, et al. · The Lancet Neurology · 81
PDF
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors
2025 · Chester Kao, Soren Charmsaz, et al. · Nature Communications · 35
PDF
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures
2024 · Chester J. Kao, Soren Charmsaz, et al. · Journal of Clinical Investigation · 31
PDF
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade
2025 · Stephanie L Alden, Soren Charmsaz, et al. · Journal for ImmunoTherapy of Cancer · 24
PDF
Baseline risk factors associated with immune related adverse events and atezolizumab
2023 · Katrin Madjar, Rajat Mohindra, et al. · Frontiers in Oncology · 21
Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy
2023 · Zia Khan, Min Jung, et al. · Genome Medicine · 19
PDF
Identification and Characterization of Immune Checkpoint Inhibitor–Induced Toxicities From Electronic Health Records Using Natural Language Processing
2024 · Hannah Barman, Sriram Venkateswaran, et al. · JCO Clinical Cancer Informatics · 18
PDF
irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets
2026 · Cosmin A. Bejan, Michelle Wang, et al. · EBioMedicine · 16
Correlation of safety and efficacy of atezolizumab therapy across indications
2024 · Gonzalo Durán-Pacheco, G Scott Chandler, et al. · Journal for ImmunoTherapy of Cancer · 9
PDF
Syncope in a middle aged male due to acute rheumatic fever.
2005 · Rajat Mohindra, H S Pannu, et al. · PubMed · 9
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines
2025 · Mari Nakazawa, Soren Charmsaz, et al. · Cancer Immunology Research · 7
An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers
2014 · Jianfeng Xu, Jan Hilpert, et al. · The Journal of Clinical Pharmacology · 6
Human Lung Alveolar Model with an Autologous Innate and Adaptive Immune Compartment
2025 · Linda Steinacher, Bruno Gjeta, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures
2025 · Chester J. Kao, Soren Charmsaz, et al. · Journal of Clinical Investigation · 3
The role of natural language processing techniques versus conventional methods to gain ICI safety insights from unstructured EHR data.
2023 · Matthew Stephen Block, Hannah Barman, et al. · JCO Global Oncology · 3
PDF
Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart
2025 · David F Lamparter, Virginia C Schmid, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.
2023 · Aanika Balaji, Stephanie Leigh Alden, et al. · Journal of Clinical Oncology · 2
Reply to Suissa and Ariel: The FULFIL Trial
2017 · David A. Lipson, Helen Barnacle, et al. · American Journal of Respiratory and Critical Care Medicine · 2
PDF
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma
2026 · Howard L Li, Soren Charmsaz, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors
2025 · Sunil Bhatt, Brian Henick, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
1178 Association between polygenic risk for thyroid dysfunction, derived from tumor panel sequencing, immune-related thyroid toxicity and overall survival in ICI treated NSCLC patients
2024 · Ericka Ebot, David Bray, et al. · Regular and Young Investigator Award Abstracts · 1
1173 Proteomic analysis in patients with immune checkpoint inhibitor (ICI) associated cardiotoxicity
2024 · Rajat Mohindra, Benjamin Fairfax, et al. · Regular and Young Investigator Award Abstracts · 1
611 Elucidating the role of human leukocyte antigens in antidrug antibody formation from a large cohort study of early-phase non-standard cancer immunotherapy trials
2024 · Tony Kam-Thong, Petar Scepanovic, et al. · Regular and Young Investigator Award Abstracts · 1
Works count: 90
Citation count: 716
H-index: 10
I10-index: 10
Year
Topic
Type